Ferroportin is an iron efflux pump that plays a key role in maintaining systemic body iron homeostasis. It is regulated by the peptide hormone hepcidin, which is made by the liver and circulates systemically. Ferroportin and hepcidin are central to assuring that iron delivery to the circulation is matched to systemic iron demand: mutations in ferroportin and hepcidin lead to inappropriate dietary iron uptake and retention, and result in hemochromatosis, a disease of iron overload. In the last grant cycle, we discovered that ferroportin and hepcidin are also manufactured in breast tissue, are essential to maintenance of iron homeostasis in the breast, and that disruption of this regulatory axis was a critical component of the transformed phenotype. In this application, we leverage these observations, as well as observations we made in the last grant period on how inflammatory, oncogenic and oxidative stress signals regulate ferreting, ferroportin and iron, to understand how iron trafficking and signaling are handled in the breast. We will explore the mechanistic link between disruptions of these regulatory circuits and their pathophysiological consequences. We will test whether blocking these pathways can modify disease progression in mouse models. We explore the fundamental iron biology that underpins these observations in three specific aims. We will explore (Aim 1) a novel autocrine and paracrine iron regulatory network in breast tissue that we recently uncovered, particularly the relationship and regulation of hepcidin and ferroportin by bone morphogenic proteins (BMPs) and their endogenous inhibitors. We will also study in detail the heretofore unrecognized transcriptional repression of ferroportin (Aim 2). Finally (Aim 3), we will address how classic systemic iron regulation mediated through liver- produced hepcidin interacts with this paracrine iron-regulatory axis in the breast. Taken together, we believe the proposed experiments break new ground by defining heretofore unknown pathways and new target tissues in the regulation of iron homeostasis and their link to disease.
This proposal will allow us to better understand iron regulation in cells and tissues. We will specifically test whether interceding in iron-regulatory pathways can modify disease processes in breast tissue. Understanding these iron- regulatory networks is a critical first step to modifying these pathways for therapeutic benefit in a wide array of conditions, including cancer and inflammatory diseases such as arthritis, as well as the anemia that accompanies inflammation and chronic disease.
|Basuli, D; Tesfay, L; Deng, Z et al. (2017) Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene 36:4089-4099|
|Deng, Zhiyong; Manz, David H; Torti, Suzy V et al. (2017) Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth. Oncotarget 8:82231-82243|
|Paul, Bibbin T; Manz, David H; Torti, Frank M et al. (2017) Mitochondria and Iron: current questions. Expert Rev Hematol 10:65-79|
|Stockwell, Brent R; Friedmann Angeli, José Pedro; Bayir, Hülya et al. (2017) Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 171:273-285|
|Torti, S V; Lemler, E; Mueller, B K et al. (2016) Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts. Clin Exp Pharmacol 6:|
|Blanchette, Nicole L; Manz, David H; Torti, Frank M et al. (2016) Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol 9:169-86|
|Manz, David H; Blanchette, Nicole L; Paul, Bibbin T et al. (2016) Iron and cancer: recent insights. Ann N Y Acad Sci 1368:149-61|
|Hatcher, Heather C; Tesfay, Lia; Torti, Suzy V et al. (2015) Cytoprotective Effect of Ferritin H in Renal Ischemia Reperfusion Injury. PLoS One 10:e0138505|
|Chakradeo, Shweta; Sharma, Khushboo; Alhaddad, Aisha et al. (2015) Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy. Mol Pharmacol 87:803-14|
|Tesfay, Lia; Clausen, Kathryn A; Kim, Jin Woo et al. (2015) Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res 75:2254-63|
Showing the most recent 10 out of 17 publications